Successful Management of Osimertinib-Induced Heart Failure
Open Access
Abstract
Cancer therapeutics-related cardiac dysfunction is currently of great concern as one of the pivotal therapeutic targets of onco-cardiology. Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. We report on a 74-year-old woman with osimertinib-induced advanced heart failure with reduced ejection fraction, which was treated by the temporal termination of osimertinib and neurohormonal blocker therapy, as well as heart rate modulation therapy using ivabradine. Despite osimertinib-induced heart failure being relatively rare, aggressive neurohormonal blocker therapy using ivabradine if applicable, as well as the temporal termination of osimertinib, might be a promising therapeutic strategy.Keywords
This publication has 12 references indexed in Scilit:
- A simple formula to predict echocardiographic diastolic dysfunction—electrocardiographic diastolic indexHerz, 2020
- How to Consider Target Heart Rate in Patients with Systolic Heart FailureESC Heart Failure, 2020
- Osimertinib-Induced CardiotoxicityJACC: Cardiooncology, 2019
- Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS).Journal of Clinical Oncology, 2019
- Management of Cancer Therapeutics–Related Cardiac DysfunctionHeart Failure Clinics, 2018
- Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patientsAnnals of Oncology, 2018
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice GuidelinesEuropean Heart Journal, 2016
- Cardiotoxicity of anticancer treatments: Epidemiology, detection, and managementCA: A Cancer Journal for Clinicians, 2016
- Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysisEuropean Journal of Cancer, 2013
- Anthracycline-Induced CardiomyopathyJACC, 2010